IR, irradiation

IR,辐照
  • 文章类型: Journal Article
    胆管细胞衰老在原发性硬化性胆管炎(PSC)的发病机理中很重要。我们发现CDKN2A(p16),细胞周期蛋白依赖性激酶抑制剂和衰老介质,PSC患者和PSC小鼠模型的胆管细胞增加(多药耐药性2;Mdr2-/-)。鉴于最近的数据表明衰老细胞的减少对不同的疾病是有益的,我们假设抑制胆管细胞衰老可以改善Mdr2-/-小鼠的疾病。
    我们使用了2种新的小鼠遗传模型来减少胆管细胞衰老:(i)p16Ink4a通过靶向激活caspase(INK-ATTAC)xMdr2-/-,其中二聚化分子AP20187促进表达p16的细胞的选择性凋亡去除;和(ii)缺乏p16和Mdr2的小鼠。Mdr2-/-小鼠也用非瑟酮治疗,一种选择性杀死衰老细胞的类黄酮分子。p16、p21和炎症标志物(肿瘤坏死因子[TNF]-α,IL-1β,和单核细胞趋化蛋白-1[MCP-1])通过PCR测量,和肝纤维化通过羟脯氨酸测定和天狼星红染色。
    AP20187治疗使p16和p21表达降低了约35%和约70%(p>0.05),分别。炎症标志物(TNF-α,IL-1β,和MCP-1)下降(60%,40%,60%,分别),纤维化降低~60%(p>0.05)。同样,p16-/-xMdr2-/-小鼠表现出减少的p21表达(70%),TNF-α表达降低,IL-1β(60%),与Mdr2-/-小鼠相比,MCP-1(65%)和减少的纤维化(〜50%)(p>0.05)。Fisetin处理降低p16和p21的表达(80%和90%,分别),TNF-α(50%),IL-1β(50%),MCP-1(70%),纤维化(60%)(p>0.05)。
    我们的数据支持胆管细胞衰老在PSC进展中的病理生理作用,靶向去除衰老的胆管细胞是一种合理的治疗方法。
    原发性硬化性胆管炎是一种纤维炎症,无法治愈的胆道疾病.我们先前报道,胆管上皮细胞衰老(细胞周期停滞和促纤维化分子的过度分泌)是原发性硬化性胆管炎的重要表型。在这里,我们证明,减少衰老的胆管细胞的数量导致炎症表达的减少,纤维化,和与疾病相关的衰老标志物。
    UNASSIGNED: Cholangiocyte senescence is important in the pathogenesis of primary sclerosing cholangitis (PSC). We found that CDKN2A (p16), a cyclin-dependent kinase inhibitor and mediator of senescence, was increased in cholangiocytes of patients with PSC and from a PSC mouse model (multidrug resistance 2; Mdr2 -/-). Given that recent data suggest that a reduction of senescent cells is beneficial in different diseases, we hypothesised that inhibition of cholangiocyte senescence would ameliorate disease in Mdr2 -/- mice.
    UNASSIGNED: We used 2 novel genetic murine models to reduce cholangiocyte senescence: (i) p16Ink4a apoptosis through targeted activation of caspase (INK-ATTAC)xMdr2 -/-, in which the dimerizing molecule AP20187 promotes selective apoptotic removal of p16-expressing cells; and (ii) mice deficient in both p16 and Mdr2. Mdr2 -/- mice were also treated with fisetin, a flavonoid molecule that selectively kills senescent cells. p16, p21, and inflammatory markers (tumour necrosis factor [TNF]-α, IL-1β, and monocyte chemoattractant protein-1 [MCP-1]) were measured by PCR, and hepatic fibrosis via a hydroxyproline assay and Sirius red staining.
    UNASSIGNED: AP20187 treatment reduced p16 and p21 expression by ~35% and ~70% (p >0.05), respectively. Expression of inflammatory markers (TNF-α, IL-1β, and MCP-1) decreased (by 60%, 40%, and 60%, respectively), and fibrosis was reduced by ~60% (p >0.05). Similarly, p16 -/- xMdr2 -/- mice exhibited reduced p21 expression (70%), decreased expression of TNF-α, IL-1β (60%), and MCP-1 (65%) and reduced fibrosis (~50%) (p >0.05) compared with Mdr2 -/- mice. Fisetin treatment reduced expression of p16 and p21 (80% and 90%, respectively), TNF-α (50%), IL-1β (50%), MCP-1 (70%), and fibrosis (60%) (p >0.05).
    UNASSIGNED: Our data support a pathophysiological role of cholangiocyte senescence in the progression of PSC, and that targeted removal of senescent cholangiocytes is a plausible therapeutic approach.
    UNASSIGNED: Primary sclerosing cholangitis is a fibroinflammatory, incurable biliary disease. We previously reported that biliary epithelial cell senescence (cell-cycle arrest and hypersecretion of profibrotic molecules) is an important phenotype in primary sclerosing cholangitis. Herein, we demonstrate that reducing the number of senescent cholangiocytes leads to a reduction in the expression of inflammatory, fibrotic, and senescence markers associated with the disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    随着免疫检查点抑制的临床成功,癌症免疫疗法的复兴已经发生。然而,免疫治疗方法的范围更广,包括T细胞参与策略,肿瘤特异性疫苗接种,抗体或免疫细胞因子。这篇综述的重点是辐射的免疫学作用以及与免疫治疗联合策略的可用证据。现有数据表明联合治疗的巨大潜力,但也提出了关于剂量的问题,分馏,时机和最有前途的多式联运策略。
    The revival of cancer immunotherapy has taken place with the clinical success of immune checkpoint inhibition. However, the spectrum of immunotherapeutic approaches is much broader encompassing T cell engaging strategies, tumour-specific vaccination, antibodies or immunocytokines. This review focuses on the immunological effects of irradiation and the evidence available on combination strategies with immunotherapy. The available data suggest great potential of combined treatments, yet also poses questions about dose, fractionation, timing and most promising multimodal strategies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Survivin是一种多任务蛋白,可以抑制细胞死亡,对有丝分裂至关重要。由于这些促生存活性及其表达与肿瘤对常规癌症治疗的抗性的相关性,survivin作为潜在的肿瘤治疗靶点受到了广泛关注。然而,关于其在分子水平上的确切作用的许多问题仍有待阐明。在这项研究中,我们询问survivin的极端C-和NH2末端是否需要它来执行其细胞保护和有丝分裂职责。当检测它们作为细胞保护剂的能力时,survivin1-120和survivin11-142都能够保护细胞免受TRAIL介导的细胞凋亡,但是当用表达survivin11-142的辐照细胞攻击时,没有存活优势。在有丝分裂期间,然而,去除NH2末端的10个氨基酸(survivin11-142)没有明显的作用,但是从C末端截短22个氨基酸(survivin1-120)阻止了survivin在后期转移到中区微管。总之,本文提供的数据表明,C末端是细胞分裂所必需的。并且NH2末端对于细胞凋亡和有丝分裂是不必要的,但对于免受辐射的保护是必需的。
    Survivin is a multitasking protein that can inhibit cell death and that is essential for mitosis. Due to these prosurvival activities and the correlation of its expression with tumor resistance to conventional cancer treatments, survivin has received much attention as a potential oncotherapeutic target. Nevertheless, many questions regarding its exact role at the molecular level remain to be elucidated. In this study we ask whether the extreme C- and NH2 termini of survivin are required for it to carry out its cytoprotective and mitotic duties. When assayed for their ability to act as a cytoprotectant, both survivin1-120 and survivin11-142 were able to protect cells against TRAIL-mediated apoptosis, but when challenged with irradiation cells expressing survivin11-142 had no survival advantage. During mitosis, however, removing the NH2 terminal 10 amino acids (survivin11-142) had no apparent effect but truncating 22 amino acids from the C-terminus (survivin1-120) prevented survivin from transferring to the midzone microtubules during anaphase. Collectively the data herein presented suggest that the C-terminus is required for cell division, and that the NH2 terminus is dispensable for apoptosis and mitosis but required for protection from irradiation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号